Angelica S. I. LoskogPhD
Loskog is the CEO of Lokon Pharma AB commercializing cancer immunotherapy invented at her lab at Uppsala University in Sweden. She was adjunct as full Professor of Immunotherapy at Uppsala University. She work as an advisor to the Swedish venture capital company Nxt2b AB, which also owns Lokon Pharma AB. She is the member, or chairman, of the board of several companies within the Nxt2b corporation such as Lokon, Vivolux, RePos Pharma, Bioimics and Hansa Medical. She was scientific advisor to other companies within the corporation such as Olink Proteomics.